Inventor · disambiguated record
Joseph G. Reynolds
Also filed as: REYNOLDS JOSEPH G
3 granted patents·6 pending applications·2 citations·filing 2013–2017
55Inventor score
Files withMERRIMACK PHARMACEUTICALS INC9
Top patents by PatentIndex Score
9 records- 0170US9226966B2Dosage and administration for preventing cardiotoxicity in treatment with ERBB2-targeted immunoliposomes comprising anthracycline chemotherapeutic agentsMERRIMACK PHARMACEUTICALS INC·Filed 2013·Granted Jan 5, 2016·2 cites·10 claims
- 0250US9610249B2Dosage and administration for preventing cardiotoxicity in treatment with ERbB2-targeted immunoliposomes comprising anthracycline chemotherapeutic agentsMERRIMACK PHARMACEUTICALS INC·Filed 2015·Granted Apr 4, 2017·0 cites·22 claims
- 0349US2017189335A1Dosage and administration for preventing cardiotoxicity in treatment with erbb2-targeted immunoliposomes comprising anthracycline chemotherapeutic agentsMERRIMACK PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 0449US2017080087A1Combination Therapies for Treating Her2-Positive Cancers that are Resistant to Her2-Targeted TherapiesMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 0548US2016045596A1Combination therapies for treating her2-positive cancers that are resistant to her2-targeted therapiesMERRIMACK PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 0645US2016038416A1Dosage and administration for preventing cardiotoxicity in treatment with erbb2-targeted immunoliposomes comprising anthracycline chemotherapeutic agentsMERRIMACK PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 0743US9913901B2Combination therapy for treating HER2-positive cancersMERRIMACK PHARMACEUTICALS INC·Filed 2013·Granted Mar 13, 2018·0 cites·22 claims
- 0839US2017258903A1Combination therapies for treating her2-positive cancers that are resistant to her2-targeted therapiesMERRIMACK PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 0937US2017022290A1Combination therapies for treating her2-positive cancersMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →